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Abstract
Tyrosine kinase inhibitors are relatively new targeted therapy drugs used for the treatment of metastatic clear cell kidney carcinoma, gastro-
intestinal stromal tumours, thyroid carcinoma and pancreatic neuroendocrine tumours during the progression of the disease. Hypothyroid-
ism or thyroid dysfunction is often a side effect of this treatment. Therefore, monitoring of thyroid hormone levels before the beginning 
and during the treatment of tyrosine kinase inhibitors is a necessity. Hypothyroidism correlates with objective response to the treatment.
Sunitinib. This is the most described tyrosine kinase inhibitor which causes hypothyroidism. The mechanism of hypothyroidism is still unclear.
Sorafenib. Symptoms of hypothyroidism occur in 18% of patients treated with sorafenib due to metastatic renal cell carcinoma.
Imatinib. Hypothyroidism is one of the most frequent side effects of the treatment. Emergent tracheotomy was necessary due to larynx 
swelling during marked hypothyroidism.
Motesanib. Hypothyroidism or increased TSH level is diagnosed in 22% to 69% of patients with metastatic differentiated or medullary 
thyroid carcinomas. The management of patients with thyroid dysfunction and related symptoms such as fatigue is undoubtedly a chal-
lenge to an oncologist. (Endokrynol Pol 2012; 63 (4): 302–306)
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Streszczenie
Inhibitory kinaz tyrozynowych są stosunkowo nowymi lekami z grupy przeznaczonej do terapii celowanych, stosowanymi w leczeniu 
nowotworów złośliwych, takich jak przerzutowy jasnokomórkowy rak nerki, stromalny nowotwór przewodu pokarmowego (GIST), raki 
tarczycy oporne na leczenie jodem radioaktywnym, przerzutowe guzy neuroendokrynne trzustki. Niedoczynność tarczycy lub dysfunkcja 
tarczycy są częstymi powikłaniami tego leczenia. Dlatego konieczne jest oznaczenie stężenia hormonów tarczycy przed rozpoczęciem 
i w trakcie leczenia inhibitorami kinaz tyrozynowych. Niedoczynność tarczycy pozostaje w ścisłym związku z obiektywną odpowiedzią 
na leczenie.
Sunitynib. Jest najczęściej opisywanym inhibitorem kinaz tyrozynowych, który wywołuje niedoczynność tarczycy. Mechanizm niedo-
czynności pozostaje niejasny.
Sorafenib. U 18% osób leczonych sorafenibem z powodu przerzutowego raka nerki występują objawy niedoczynności tarczycy.
Imatynib. Niedoczynność tarczycy jest jednym z najczęstszych powikłań leczenia imatinibem. W przebiegu nasilonej niedoczynności 
występowała konieczność wykonania pilnej tracheotomii z powodu obrzęku krtani.
Motesanib. Niedoczynność tarczycy lub podwyższone stężenie TSH jest rozpoznawane u 22–69% chorych na przerzutowego zróżnico-
wanego lub rdzeniastego raka tarczycy.
Postępowanie z chorymi z dysfunkcją tarczycy i ze współistniejącymi objawami, takimi jak zmęczenie, jest niewątpliwie wyzwaniem dla 
onkologa. (Endokrynol Pol 2012; 63 (4): 302–306)
Słowa kluczowe: niedoczynność tarczycy, inhibitory kinazy tyrozynowej
Introduction
Tyrosine kinase inhibitors are enzymatic receptor 
proteins which catalyse the transfer of phosphate 
from ATP to tyrosine present in the peptides. They are 
involved in the proliferation, angiogenesis, and inva-
siveness of the tumour. Tyrosine kinase inhibitors are 
the new multi-targeted therapy drugs used to treat 
haematological and solid tumours. They influence 
oncogenesis directly or indirectly through blocking 
tyrosine kinases. Tyrosine kinase inhibitors are not 
specific for one kind of tyrosine kinase, but most of 
them interact with vascular endothelial growth fac-
tor (VEGF), its receptor and platelet-derived growth 
factor receptors (PDGFR) [1].
Although they have the same mechanism of action, 
they differ from each other in the spectrum of targeted 
kinases, their pharmacokinetics, as well as specific ad-
verse effects [2]. Erlotinib and gefitinib give the main 
spectrum of adverse events on skin and hair [2]. The 
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commonest side effects associated with dasatinib and 
nilotinib are haematologic and cardiological [3].
Primary hypothyroidism is a rare complication of 
oncological treatment. Mainly interferon alpha and 
interleukin 2 cause hypothyroidism. Tyrosine kinase 
inhibitors often cause this side effect.
The first report on interaction between these drugs 
and thyroid function was published in 2005. Many 
papers have been published on this subject to date. 
The most important publications devoted to hypothy-
roidism as a result of treatment with tyrosine kinase 
inhibitors are set out in Table I [1].
The influence of the four multi-targeted therapy 
drugs i.e: sunitinib, sorafenib, imatinib, and motesanib 
on thyroid function are presented in this article.
Sunitinib
Sunitinib is an oral multi-targeted vascular en-
dothelial growth factor and receptor tyrosine kinase 
inhibitor used for metastatic renal cell cancer and 
imatinib-resistant gastrointestinal stromal tumours, 
and recently in pancreatic neuroendocrine tumours 
(PNT) during the progression of the disease [4–6]. 
It is administered in a dose of 50 mg daily for four 
weeks, and the next two weeks of withdrawal, in PNT 
in a dose of 37.5 mg daily.
Retrospective studies indicate that sunitinib induces 
hypothyroidism in 53% to 85% of patients and prospec-
tive studies show that hypothyroidism is induced by 
sunitinib in 36% to 46% of patients [7–11]. The onset of 
hypothyroidism is unpredictable because significant dif-
ferences in gender, age and severity of neoplastic disease 
are not observed. In general, hypothyroidism shows 
progressive worsening. Only in some cases is a sudden 
development of severe hypothyroidism diagnosed [8]. 
Hypothyroidism is revealed either in the first or second 
week of sunitinib therapy. Several authors have also 
found that TSH levels were elevated at the end of ON 
periods (four-week daily administration) and normal-
ised at the end of OFF periods (two-week withdrawal), 
leading to intermittent hypothyroidism. After several 
treatment cycles, the baseline TSH levels seemed to 
increase, revealing a permanent hypothyroidism [1, 8]. 
Increased TSH (thyroid-stimulating hormone) level 
and decreased T3 (triiodothyronine) level are observed. 
Decreased T4 (tetraiodothyronine) level and free tyrox-
ine index are seldom observed [9]. In general, thyroid 
impairment is diagnosed after two cycles of treatment 
[9]. According to Wong et al., hypothyroidism occurs 
on average after five months of therapy [10]. The mean 
time of onset of hypothyroidism after initiation for 
sunitinib therapy ranges from 12 to 50 weeks [11]. The 
risk of development of hypothyroidism increases with 
increasing duration of sunitinib therapy [11]. Symptoms 
of hypothyroidism such as: fatigue, cold intolerance, 
fluid retention, anorexia, skin and hair changes can be 
found in about 84% of patients with thyroid dysfunction 
[9]. Approximately 50% of those treated with sunitinib 
require supplementation of thyroid hormones, and 
levothyroxine reduced symptoms in 50% of treated 
patients [1, 10]. Because of this, routine monitoring of 
thyroid hormones is warranted before beginning, and 
every 2–3 months during, treatment with sunitinib 
[8–10, 12–15]. There is disagreement on the subject of 
the frequency of thyrotoxicosis caused by sunitinib. 
Table I. Treatment of tyrosine kinase inhibitors and hypothyroidism (according to [1])
Table I. Leczenie inhibitorami kinazy tyrozynowej a niedoczynność tarczycy (wg [1])
Author, year of 
publication
Drug Number of subjects Indication Hypothyroidism [%]
Desai, 2006 Sunitinib 42  GIST  36
Mannavola, 2007 Sunitinib 24  GIST 71
Rini, 2007 Sunitinib 66 Renal cell carcinoma 85
Wong, 2007 Sunitinib 40 Solid tumours (mainly GIST) 53
Wolter, 2008 Sunitinib 59 Renal cell carcinoma/GIST 61
Schmidinger, 2011 Sunitinib/sorafenib 87 Renal cell carcinoma 36
Tamaskar, 2007 Sorafenib 39 Renal cell carcinoma 18
de Groot, 2005 Imatinib 11 Medullary thyroid carcinoma/ 
/GIST
100 in athyreotic subjects
de Groot, 2007 Imatinib 15 Medullary thyroid carcinoma 100 in athyreotic subjects
Sherman, 2008 Motesanib 93 Differentiated thyroid cancer 22
Schlumberger, 2009 Motesanib 91 Medullary thyroid carcinoma 29
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According to some authors, thyrotoxicosis rarely occurs 
[16]. According to other sources, thyrotoxicosis is fre-
quently diagnosed, which could be related to frequent 
monitoring of thyroid hormone level during treatment 
[13]. Sakurai presented sunitinib-induced thyrotoxicosis 
and destructive thyroiditis. Destructive thyroiditis is 
diagnosed based on increased thyroglobulin level, a low 
radioactive uptake, increased free thyroxine level, and 
suppressed TSH level. It is characterised by transient 
thyrotoxicosis with complete recovery. Sometimes it 
is followed by transient and persistent hypothyroid-
ism [17]. An algorithm to diagnose and treat thyroid 
dysfunction during sunitinib treatment is presented 
in Figure 1 [16].
The pathophysiologic mechanism of hypothyroid-
ism induced by sunitinib is still unclear [4, 13]. Different 
mechanisms have been considered in order to explain 
this hypothyroidism.
The influence of progressive depletion of functional 
reserves, selected inhibition iodine thyroidal uptake, 
direct effect on sodium iodide symporter (NIS) or TSH 
receptor or thyroid atrophy as a result of blocking 
the gland vascularisation has been investigated [9]. 
Decreasing blood flow in vessels as a result of VEGFR 
blocking decreases shrinkage of thyroid gland dimen-
sions [18–20].
After definitive completion of sunitinib, TSH level 
returns in the normal range after a maximum period of 
60 days. This suggests that hypothyroidism is transitory 
and it shows that blocking of iodine uptake is directly 
related to the drug administration, similarly to the other 
side effects of the drug [8]. On the other hand, a study 
on rat thyroid cells excluded the possibility of iodine 
uptake inhibition [4].
Sunitinib inhibits thyroid peroxidase activity de-
creasing thyroid hormones synthesis, and in this way 
sunitinib contributes to hypothyroidism [10].
Individual cases of lymphocytic thyroiditis during 
sunitinib treatment have been described, suggesting 
that sunitinib could trigger an autoimmunological pro-
cess in the thyroid gland [16, 21]. However, the direct 
toxic influence of thyroid cells and autoimmunological 
background have been excluded [8]. There is a lack of 
cytological evidence for the presence of thyroid tissue 
inflammation changes, and on this basis, a hypothesis 
has been put forward that hypothyroidism is caused by 
sunitinib-induced follicular cell apoptosis [7].
Hypothyroidism during sunitinib treatment of 
patients with metastatic renal cell cancer can correlate 
with objective response to this therapy [22].
Hypothyroidism can be considered as a marker of 
response to treatment with this drug.
Figure 1. Algorithm to diagnose and treat thyroid dysfunction during sunitinib (according to [16]); TSH — thyroid-stimulating 
hormone; T4 — tetraiodothyronine; UNL — upper limit of normal
Rycina 1. Algorytm diagnozowania i leczenia dysfunkcji tarczycy podczas leczenia sunitynibem (wg [16]); TSH — hormon tyreotropowy; 
T4 — tetrajodotyronina; UNL — górna granica normy
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Sorafenib
Sorafenib is an oral multi kinase inhibitor such as: raf, 
VEGFR1, VEGFR2, VEGFR3, protein c-Kit, PDGFR 
beta, RET, fms. It is approved for metastatic renal cell 
carcinoma and unresectable hepatocellular carcinoma 
[1, 23]. Sorafenib is effective both in metastatic and 
locally advanced medullary thyroid carcinoma and 
nonmedullary thyroid carcinoma [24]. The adminis-
tration of sorafenib is 800 mg daily. One cycle lasts 
four weeks. Hypothyroidism is one of the side effects 
of sorafenib, but it does not occur as frequently as 
with sunitinib [22, 23]. Hypothyroidism can persist 
after completion of sorafenib treatment [1]. Sorafenib 
is associated with increased TSH levels in 33% of thy-
roid carcinoma patients [25]. Biochemical features of 
hypothyroidism occur in 18% of those treated with 
sorafenib due to metastatic clear cell renal carcinoma 
[23, 26]. Dysfunction of thyroid is usually of short 
duration and it seldom requires supplementation [22]. 
Subclinical hypothyroidism is related to the rate of 
objective response. This indicates that hypothyroid-
ism can serve as a marker of response to therapy 
with sorafenib due to metastatic renal cell carcinoma 
[22]. Abdulrahman hypothesised that sorafenib may 
influence the activities of iodothyronine deiodinases 
(D1, D2 and D3). It probably causes enhanced T4 and 
T3 metabolism and may contribute to hypothyroidism 
during sorafenib therapy [24].
Imatinib
Imatinib is an oral tyrosine kinases inhibitor such as: 
Bcr-Abl, PDGFR alpha, PDGFR, c-Fms, c-Kit [1, 14]. 
Imatinib is approved for chronic myeloid leukemia, 
metastatic gastrointestinal stromal tumours and der-
matofibrosarcoma [1, 14, 27]. The efficacy of imatinib has 
been investigated in medullary thyroid cancer. There 
was no objective response, but toxicity was significant. 
Hypothyroidism in G3 degree was the commonest 
side effect. It occurred in 33% of patients treated with 
imatinib [14].
Hypothyroidism is reversible through increasing 
doses of hormones thyroid supplementation [28]. In 
a few patients with significant hypothyroidism, there 
occurred swelling of the larynx which required emer-
gent tracheotomy [14]. Patients with hypothyroidism 
who are taking imatinib should have the exact in-
creasing level of thyreotropins monitored. It indicates 
marked hypothyroidism and requires escalation of 
hormone thyroid dosage [28].
Dora et al. did not prove the effect of imatinib on 
thyroid dysfunction. There was no correlation between 
TSH level and dose, duration of treatment or the cu-
mulative dose of imatinib [27]. But these results should 
be interpreted with great caution because of the small 
number of patients enrolled in the trial; even a correla-
tion between imatinib treatment and dysfunction of 
thyroid has not been confirmed so far.
Motesanib (AMG 706)
Motesanib is an oral tyrosine kinase inhibitor such 
as: VEGR r1 VEGR r2, VEGR r3, PDGFR, RET, KIT 
[1, 29, 30]. Clinical trials have been conducted related 
to the efficacy of motesanib in radioiodine-resistant 
differentiated thyroid carcinoma, medullary thyroid 
carcinoma and other solid tumours [1, 29–31]. The ac-
tion of motesanib can be doubled through its influence 
on both thyroid tissue and thyroid hormones [1]. In 
a two-phase trial among patients with metastatic or ad-
vanced differentiated or medullary thyroid carcinoma 
treated with motesanib, hypothyroidism occurred in 
22% of patients with differentiated thyroid carcinoma 
and in 29% to 61% of patients with medullary thyroid 
carcinoma [30, 31]. Therefore the dose of levotyroxine 
required escalation [1].
It appears that motesanib is a new achievement in 
the treatment of differentiated and medullary thyroid 
carcinomas.
Conclusions
Hypothyroidism is a frequent side effect of tyrosine 
kinase inhibitors treatment.
A thyroid function test assessment is necessary 
before beginning and during therapy with tyrosine 
kinase inhibitors.
Thyroid hormone replacement therapy should be 
considered in the case of clinical explicit hypothyrodism.
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